Microsoft Word - SRA revised RFP final

Senior Research Award

APPLICATION GUIDELINES, PROCESS and FORMAT

Effective for Letters of Intent and Proposals due on or after May 5

, 2019

Spring/Summer

Fall/Winter

Letter of Intent November 5

, 5:00 pm EST May 5

, 5:00 pm EST

Full Proposal

January 28

5:00 pm EST

July 20

5:00 pm EST

Review

Period

April

–

May

October

–

November

Project Start

Date

July January

*Should the deadline date fall on a weekend or national holiday, the deadline will be extended to

the following business day.

Crohn’s & Colitis Foundation

MISSION:

To cure Crohn’s disease and ulcerative colitis,

and to improve the quality of life

of children and adults affected by these diseases.

http://www.crohnscolitisfoundation.org

General Submission Inquiries: grant@crohnscolitisfoundation.org

INTRODUCTION

The Crohn's & Colitis Foundation (Foundation) was established in 1967 to find the cause of and

cure for Crohn's disease and ulcerative colitis, collectively known as inflammatory bowel disease

(IBD). Support for our research program is provided by members and concerned individuals,

corporations and philanthropic foundations.

The guiding mission of the Foundation is to stimulate and encourage innovative research in the

basic, translational and clinical biosciences, which is likely to increase our understanding of the

etiology, pathogenesis, therapy, and prevention of IBD. A focus on human mechanisms in IBD is

particularly important for preclinical research.

Each year, the Foundation receives approximately 300 requests for Senior Research, Training,

and Student support. All proposals are subjected to peer review to identify the most meritorious

and innovative projects for funding.

The goal of the Senior Research Award (SRA) is to provide established researchers with funds

to generate findings that have an impact on the field of IBD to advance the mission of the

Foundation. This impact could be evaluated by various measures, including follow-on funding

from other sources, such as the National Institutes of Health (NIH), publications with high impact,

and related patents or citations within patents.

APPLICANT ELIGIBILITY

At the time of application, the applicant must:

 hold an MD, PhD, or equivalent terminal degree and must be employed by an institution

(public non-profit, private non-profit, or government) engaged in health care and/or health

related research

 have attained independence in his/her research efforts

 be corresponding author for publications in the investigator’s main area of research

interest

Eligibility is not restricted by citizenship or geography.

PROPOSAL ELIGIBILITY

 The submitted research proposal must address IBD.

 Only one proposal may be submitted for this award per submission date.

 Applicants for an SRA may not simultaneously apply for a Training Award (Career

Development or Research Fellowship Award).

 Applicants for an SRA may not simultaneously submit another application focused on the

same research topic for a Litwin IBD Pioneer award, Clinical Research Network Award or

Research Initiative.

 Successful applicants may not hold concurrent Foundation SRAs; however, applications

for new projects may be submitted 6 months prior to the termination of awardees current

grant.

APPLICATION PROCESS

LETTER OF INTENT

Each applicant must submit a letter of intent (LOI) prior to submitting a full proposal for

consideration. The LOI is reviewed seriously by the review committee and determines whether or

not a full application is recommended to be submitted. Each section of the LOI must be completed

fully to be eligible for funding consideration.

Resubmissions do not require an LOI. PIs intending to resubmit an application need to inform

the Foundation by the LOI submission deadline by sending an email to

loibypass@crohnscolitisfoundation.org with the following information:

 Subject line: Resubmission – LOI Bypass Request

 Body of email: PI name, project title, and original proposal number

Resubmissions are allowed within three years of the initial application submission. After three

years, a new LOI is required.

Components of Letter of Intent (LOI)

Please complete the LOI online in proposalCENTRAL, and adhere to the character

limitations of each section and the other requirements as outlined.

Type of Research

Select one of the following

 Basic

 Translational

 Clinical (Please see section on Special Instructions for Clinical Trials, if applicable)

Challenges Priority

Please check one or more of the Challenges priority areas that is addressed by your project. You

may check “other,” but please be prepared to explain why the topic of your research proposal

should be considered a priority area for funding. Link to the Challenge priority areas are here.

Type of Disease

Select one of the following:

 Crohn’s disease

 Ulcerative colitis

 Inflammatory Bowel Disease non-specified

Eligibility Determination

Answers to the questions determine your eligibility for an SRA to enable you to continue with the

application process.

Principal Investigator (PI)

PI is defined as the one person responsible to the Foundation for scientific and technical direction

of the project. While a project can have Co-PIs and senior collaborators, only one person and

awardee organization can be the point of contact responsible for technical and financial

management of the award scientific outcomes and reports.

Organization Information

This indicates where the PI is located and where the study will take place. The Foundation does

not make awards to individuals.

Key Personnel

Fill in key personnel, titles and affiliations

Project Title

Fill in the project title. Do not use abbreviations.

Scientific Summary of Project

The Scientific Summary should provide a clear overview of the proposed work, including

background (or hypothesis and its supporting rationale) and specific aims of the study. It should

be concise but allow the review committee to assess the scientific merit and recommend it for full

submission.

Relevance and Significance of the Project to IBD

Provide a description of how this project addresses unmet needs in IBD, is related to the

Foundation’s research priorities, outlined in Challenges in IBD, and how it will further both

research and the Foundation’s mission. The LOI must state how the research proposal is

related to an area outlined in Challenges in IBD (link:

https://academic.oup.com/ibdjournal/issue/25/Supplement_2), or if not related to areas outlined

in Challenges in IBD, the LOI must state why the research proposal is so compelling that it

should be considered a priority for funding. If it is a proposal for preclinical research, then

the project must demonstrate its relevance to human IBD mechanisms. Scoring will be

negatively impacted if the LOI does not address these areas.

Attachments

Please upload the following to this section:

 NIH Biosketch/CV for applicant

 Up to three relevant publications (optional)

FULL APPLICATION

After review of LOIs, selected applicants will be informed whether their proposals have been

selected for full application submission. There is an approximate three-week turnaround on LOI

decisions after the LOI deadline has occurred.

Components of Full Application

TITLE PAGE

Project Title

Fill in project title. If this is a resubmission, the title should be the same as the original application.

Type of Research

Select one of the following

 Basic

 Translational

 Clinical (Please see section on Special Instructions for Clinical Trials, if applicable)

Challenges Priority

Please check one priority area that is addressed by your project, or if not related to Challenges in

IBD, why the research proposal is so compelling that it should be considered a priority for funding.

If it is a proposal for preclinical research, then the project must demonstrate its relevance

to human IBD mechanisms.

Type of Disease

Select one of the following:

 Crohn’s disease

 Ulcerative colitis

 Inflammatory Bowel Disease non-specified

APPLICANT/ PI

Principal Investigator

PI is defined as the one person responsible to the Foundation for scientific and technical direction

of the project. Although co-PIs are permitted, only one can be indicated as the main point of

contact.

Organization Information

This is where the lead PI is located and where the study will take place.

INSTITUTION AND CONTACTS

At the time of proposal submission, appropriate administrative officials will be required to sign off

and submit the application. Please provide the name and address of the person, at the grantee

institution, who will administer the grant. Please ensure that appropriate parties responsible to

upload financial reports, fully executed award letters, organization assurances, and other

institutional documents is given “Editor” or “Administrator” role for the proposal. Failure in

observing that aspect may result in administrative delays.

KEY PERSONNEL

Please note any key members of this project such as collaborators, etc.

LAY SUMMARY

This summary for general audience should be a clear, concise overview in simplified language,

appropriate for non-scientific reviewers. The lay summary should include the following

information:

 What question will this project attempt to answer?

 Why is this question important to IBD? How would the results significantly advance the

field of IBD research or impact patient care or quality of life?

 How does the research address the Challenges in IBD? or if not related to Challenges in

IBD, why the research proposal is so compelling that it should be considered a priority for

funding?

 What is the study design? How is it innovative?

 How do the hypothesis and specific aims fit with the Foundation’s scientific priorities?

 If the research is successful, what next steps are needed to advance to the Foundation’s

mission to find cures for IBD and/or to improve quality of life for IBD patients?

In addition, include a brief glossary of any scientific terms included in your lay summary.

SCIENTIFIC SUMMARY

The Scientific Summary should provide a clear overview of the proposed work, including

background, hypothesis and its supporting rationale, and specific aims of the study. It should be

concise but allow the review committee to effectively assess the scientific merit.

Relevance of the Project to IBD

Provide a description of how this project is explicitly related to IBD and how it will further research

to achieve the Foundation’s mission. If it is preclinical research, then the project must demonstrate

its relevance to human IBD mechanisms or explain why this should not be a priority for this

particular research.

The above three sections will be evaluated as part of the application as well as used to

inform the Foundation’s National Board of Trustees and the general public about the

funded project, therefore proprietary or confidential information should not be included.

BUDGET

Project Start Date

Date on which you expect to start this project. Funded applications for the Spring cycle would

begin on July 1

. Funded applications in the Fall cycle would begin on January 1

of the

following year.

Estimated Length of Project

SRA projects can range from 12 to 36 months duration.

Percentage Effort

Inform the effort (in percentages) you estimate that will be needed to complete the proposed

project. A minimum of 2 to 5% effort is required for the PI of an SRA. Describe how your time (in

percentages) is allocated in your current position at this institution. An institutional representative

will be required to confirm this information as part of the proposal submission process.

Percentage of Fringe Benefits Paid by Your Institution

Inform the applicable percentage of fringe benefits.

Detailed Budget

The total budget can be requested for up to three years. The request per year, including direct

and indirect costs, may not exceed $115,830. The Foundation indirect cost rate for the SRA is

10%. (So maximum request per year allowed is $105,300 in direct costs + $10,530 in indirect

costs.)

The requested budget should reflect the personnel and other expenses to carry out the proposed

activities.

SRAs are not meant to be a major source of a PI’s salary. The award can support a portion of the

PI's salary commensurate with the time allotted to the project. The salary request for the PI should

be calculated as a percentage of the NIH salary cap, which is limited to the current Executive

Level II of the Federal Executive pay scale.

Requests for major equipment purchases (over $5,000) are generally not considered. Any

equipment purchased under a Foundation award is for the use of the PI, his/her collaborators

and/or other researchers or trainees involved in this research project. Title to equipment shall be

vested in the institution with which the PI is associated. In the event of an award transfer to another

institution, equipment necessary for continuation of the research project purchased with the grant

funds should be transferred to the new institution. Title to such equipment shall be vested in the

new institution.

Indirect costs over subcontracts:

 The prime recipient institution may request up to a maximum of 10% of the first $25,000

of each subcontract.

 Subcontracting institutions may request up to 10% of indirect costs.

 The awardee institution is responsible for all oversight of the subcontract and must include

financial accountings for the subcontract(s) in the financial reports

Budget Justification

It is the applicant's responsibility to justify the budget. Items not adequately justified will

not be supported. Please provide a budget justification for the amount requested. Details should

be provided to allow reviewers to assess how the requested amounts for personnel and non-

personnel expenses will be spent to carry out the proposed activities.

CURRENT AND PENDING SUPPORT

Provide information on currently active projects and proposals pending review.

For pending applications, attach an abstract for each application you list in this section as an

appendix in the Attachments Section.

Important Note on Scientific and Funding Overlap

The Crohn’s & Colitis Foundation reserves the right not to fund projects that are supported all or

in part by another agency. Projects are considered to overlap if there are any shared Specific

Aims or budgetary overlap or overlap of percent of effort dedicated to the other project. The review

committee will make the final decision regarding any questions of overlap.

Clinical trials requiring Foundation support in addition to outside support will be considered.

Please see section on Special Instructions for Clinical Trials, if applicable.

Additionally, there is an exception for institutional support (PI faculty package, discretionary funds,

etc.). If this is applicable to this proposal, a description of any institutional support provided by the

institution should be uploaded to the section “Evidential Enclosure”. The details should include

institutional commitment to the support of the applicant’s salary; and the current term of the

applicant’s appointment. Please note that the institutional support does not decrease the chances

of obtaining support from the Foundation, rather, such support is frequently considered by the

review committee as important evidence for institutional commitment to the proposed research

project.

ORGANIZATION ASSURANCES

Human/Animal Studies Approval

All activities involving human subjects or vertebrate animals must be approved by an appropriate

institutional review board (IRB) or equivalent within two months of the award date and is

required for study activation and initial payment. Nevertheless, please indicate with “Yes” or

“No” response, and if yes indicate date of approval and upload approved protocol in the

Attachments Section.

ATTACHMENTS

Research Plan/Protocol

The description of the proposed research project must include the following items in sufficient

detail to permit evaluation of the scientific merit of the study.

This section is limited to 7 pages, single spaced (1/2 inch margins). The lengths indicated

below are included as a guideline and not required. HOWEVER, applications exceeding the

page limit will not be reviewed.

Please see section below on Special Instructions for Clinical Trials, if applicable.

Overall Objectives (one or two paragraphs)

 General scientific objectives

Specific aims (1 page)

 Describe concisely and realistically what the specific research described in this

application is intended to accomplish. Specifically outline Aims for year 1, year 2 or year

3, goals, deliverables and timelines. State any hypotheses to be tested.

Background -including preliminary data (2 pages)

 Outline the previous work in the area by others, and the preliminary data or previous

studies by the investigator(s). Enough preliminary data should be included in the

application to demonstrate that the project is feasible, and that the investigator is likely to

complete the project successfully in the duration of the grant.

Methods and Materials to be used (3 pages)

 Provide a detailed discussion of the experimental design, procedures, and materials to

be used to accomplish the Specific Aims.

 Describe protocols, including methods for new techniques, and explain the advantages

over existing methodologies.

 Discuss the kinds of data expected to be obtained and the means by which data will be

analyzed and interpreted.

 Justify the use of any animal models (i.e., choice of species, number used, etc.).

 Discuss potential difficulties and/or limitations of the proposed procedures and

alternative approaches to achieve aims.

Significance and Relevance of the proposed research to IBD (Crohn's disease and/or

ulcerative colitis) (1 page) Please note that Significance/Relevance to IBD is a separately

scored section of the proposal and is considered very seriously to determine whether the topic

of research addresses a research priority.

 Justify the significance of the results of this project to the understanding of the etiology,

pathogenesis, therapy, and prevention of IBD. Specifically identify the gaps this project is

intended to fill as it relates to the priorities outlined in Challenges in IBD (add link) or if not

related to Challenges in IBD, why the research proposal is so compelling that it should be

considered a priority for funding.

 For preclinical research, the project must demonstrate its relevance to human IBD

mechanisms or explain why this should not be a priority for this particular research.

Facilities Available for Proposed Studies (one or two paragraphs)

 Describe the facilities available, including square footage, equipment, animal care

facilities, and other environmental factors. Pay attention to those items required for

successful completion of this proposal. Include a description for each facility to be

involved.

 Sufficient information must be included to demonstrate the high quality of the PI’s

research, the co-investigators, available research resources and the applicant institution

and its support of the project. Should particular equipment or lab space be required for

the project and provided by the institution, include a letter of commitment of these

resources.

Bibliographic References (3 pages)

 Literature citations should be listed in this section, at the end of the Research Plan.

These are not counted as part of the 12-page limit.

Reply to Previous Review (REQUIRED for Resubmission applications ONLY) (1 page)

 For Resubmissions, upload a letter that clearly and succinctly addresses the points

raised in the previous review and direct the reviewer to the specific sections of the

Research Protocol where revisions have been made. Revised portions of the text

changed in response to the reviewers’ comments should be highlighted.

 In this section, include copies of the following

o Budget pages of previous application

o Overall objectives and specific aims of previous application

Letters of Collaboration

o Attach letters of collaboration from all senior personnel cited in the proposal but not

included in the budget. The letter should be concise and confirm the participation of the

collaborator in the project and in what capacity (providing samples, reviewing protocols or

publications, etc.)

Applicants’ CV/NIH Biosketch

Attach the CV/NIH Biosketch for the applicant.

Human and/or Animal Approvals

Upload IRB approvals for human and animal research. If a protocol has not yet been approved,

one will be required prior to award execution.

New Vendor Form and W9

Complete so that, in the event of award, the institution is eligible to receive payment. This

document should include the name of institution as listed on the W9 as well as an attached W9

for reference. This is required even if institution has received prior funding from the Crohn's &

Colitis Foundation

Appendices

Uploaded reference material may include:

 Article references

 Abstracts

 Original Pictures

 Other Letters of Support

APPLICATION FORMAT

 PI name must be clearly identified on the header of each attachment (not applicable to

letters of collaboration and protocols).

 12-point Times New Roman or 11-point Arial is the minimum font size for the text of the

application. A 10-point Times New Roman or 10-point Arial font type may be used for

figures, legends, and tables.

 Single-spaced text is acceptable, and space between paragraphs is recommended.

 Margins should be at least 1” inch all around, unless a form with different margins is

supplied in the Application Templates or Forms.

SIGNATURE PAGE

A signature page signed by the applicant AND Institutional Officer is required at the time of

proposal submission and must be uploaded.

SPECIAL INSTRUCTIONS FOR FOREIGN APPLICANTS

Budget request must be in U.S. dollars. Awards will be made in U.S. dollars.

Please be aware that you should give more details than you might be accustomed, especially in

the areas of background material and preliminary data, experimental design, and available

facilities, budgetary items (particularly percent of effort and salary requests for key personnel).

Please contact the Foundation at grant@crohnscolitisfoundation.org with any questions or

seeking additional information.

All materials MUST be submitted in English.

SPECIAL INSTRUCTIONS FOR CLINICAL TRIALS

The NIH considers a clinical trial to be any study in which one or more human subjects are

prospectively assigned to one or more interventions to evaluate the effects of those interventions

on health-related biomedical or behavioral outcomes. Should your proposal fall into this category

it is necessary that your Research Plan include the following sections in addition to those listed

above.

Specific Aims:

These should include a delineation of the primary and secondary end points to be measured with

an appropriate explanation of the relative importance of the various end points.

Significance:

The application should clearly state the need for the study and how the results would impact on

the prevailing practice in this area.

Experimental Design and Method:

The inclusion and exclusion criteria should be listed, and the procedure(s) to be utilized for

assignment of patients to experimental groups should be described. The study design for the

interventions to be used should be presented in detail including the rationale for the design chosen

and procedures to assure compliance with and implementation of the proposed protocol.

Potential biases in the proposed protocol and how they will be addressed should be presented.

Clinical, laboratory, and physiological tests should be described including methods of

randomization. Finally, assumptions and calculations to arrive at the proposed sample size

should be included.

The availability of patients for the proposed study, including the specific characteristics that are

required for the group should be presented. Approaches should be outlined that will be used for

the recruitment, retention, and follow-up of the required number of patients. Projected rates of

patient enrollment should be included in a targeted enrollment table. Data should be presented

supporting recruitment, enrollment and retention feasibility and power analyses to support the

number targeted for enrollment. If enrollment falls behind projected levels, funding may be

delayed or terminated.

Plans should be described for patient protection, including informed consent, monitoring of data

for safety, and early termination as required. At the time of acceptance of funding, appropriate

informed consent forms, certification of approval from the Human Studies Committee (or its

equivalent) for each participating institution, and GCP training certificates should be submitted to

the Foundation.

The organization of the study and how the trial will be managed should be described, including

the function of any internal or external advisory committees and any data and safety monitoring

groups. In multicenter trials, you should provide a description of the responsibility and role of a

data coordinating center, and policies and methods concerning blinding of study results.

Accordingly, a plan should be submitted describing the procedure for the coordination of all

participating centers. The Crohn’s & Colitis Foundation does not assume responsibility for the

conduct of the activities that the grant supports or the acts of the grant recipient as both are under

the direction and control of the grantee institution and subject to the institution’s medical and

scientific policies. Grantee institutions must safeguard the rights and welfare of individuals who

participate as subjects in research activities by reviewing proposed activities through an

Institutional Review Board (IRB), as specified by the NIH Office for Human Research Protections,

US Department of Health and Human Services. These policies apply to applicants and applicant

institutions as well. Finally, a timetable for completion of the various phases of the trial should be

presented.

A procedure or plan for data management should be described, including data collection forms, if

available. Data analysis methodology linking the analyses to the hypotheses to be tested should

also be included. Primary and secondary end points should be clearly defined, justified, and

related to the power calculations.

Evidential Enclosures:

Enclose letters of commitment from each participating center, signed by the cooperating

investigator and business official. In addition, informed consent forms and evidence of Human

Studies approval from all participating centers should be included in this section.

Curriculum Vitae:

Biographical sketches of all key investigators, center directors, and multidisciplinary team

members should be included.

Facilities:

Clinical, data management, and laboratory facilities should be described in detail for all

participating institutions, where applicable.

Budget:

A total overall budget and a complete justified budget for each year of support should be

presented. If the trial is designed for more than the three-year period, complete justified budgets

for the future years and a plan for securing funding for additional year(s) must be included. If the

study involves multiple centers, a composite matrix should be submitted, where applicable. If

parts of the costs of the total trial are to be provided by other sources, these contributions should

be presented in detail along with supporting letters from appropriate individuals and/or institutions.

Please add additional budget information into the online template.

REVIEW PROCESS

Peer Review of Applications

SRA applications are reviewed by the review committees, which are composed of basic and

clinical IBD researchers in a variety of fields. These committees generally have between 15-20

members, including leaders in their areas of expertise and 2-3 lay reviewers. In addition, ad-hoc

members may be added in order to provide expertise in certain area(s), depending on the

composition of topics of the submissions. Each application is assigned a primary, secondary, and

lay reviewer.

Reviewers are required to prepare a written evaluation of the application, addressing the following

separately scored criteria:

 Overall Impact: All research supported by the Foundation must examine research

questions that have a direct application to Crohn's disease and/or ulcerative colitis,

preferably with evidence that links the research question to mechanisms that are relevant

to patients with IBD. It is the applicant's responsibility to explain the relevance of the

proposal to human IBD or why the research should be prioritized without demonstrating

this relevance.

 Significance and Challenges in IBD: The significance of the proposed studies in advancing

unmet needs in IBD and how the application addresses the Challenges in IBD will be

evaluated. If the application does not address at least one category of the Challenges in

IBD, the case for why the research proposal is so compelling that it should be considered

a priority for funding will be evaluated.

 Research Plan: This includes excellence of hypothesis, experimental design, and the

likelihood of the proposed research to produce significant new information that will

enhance the understanding of IBD to enable the Foundation to achieve its mission of

finding cures for IBD and/or improving the quality of life of those living with these diseases.

 Excellence of Investigator and Research Environment: Investigator qualifications to be

examined are scholastic background, research experience, achievements and

publications. Environmental criteria include availability of appropriate space and

equipment, consultants, etc.

Members of the review committees meet to discuss and select the most scientifically sound and

impactful proposals. Selected proposals are scored, using a 9-point rating scale (1 =

exceptional; 9 = poor) based on the above-mentioned criteria and then ranked against other

submitted proposals.

Review by Grants Council

Projects in the fundable range are examined and ranked by the Grants Council in respect to the

Foundation's goals, as outlined in the document, "Challenges in IBD". The link can be found

here: https://academic.oup.com/ibdjournal/issue/25/Supplement_2.

Board of Trustees Approval

The Grants Council recommends the proposals for funding to the Board of Trustees, which is then

responsible for making the final decision to approve funding.

STATEMENT OF COMMITTEE IMPARTIALITY

To ensure that the peer review process undertaken by the Foundation’s review committees is fair

and unbiased, the following procedures are in place:

An Ad Hoc Review Committee is set up to review any of the following:

 Application submitted or sponsored by a member of one of the review committees

 Applicant mentored by a Fellowship Grant Review Committee member/chair in the last

five years.

 A Senior or Clinical Research Grant Review Committee member is a key personnel with

5% or more effort listed in budget of the grant application

If a committee member answered "yes" to any of the following, that will be considered a conflict

and the reviewer will not participate in the evaluation of that application.

 Are you a key personnel/collaborator on this proposal (<5% effort)?

 Have you and the applicant worked at the same institution in the last three years?

 Have you collaborated with the applicant in the last three years?

 Have you co-authored/published a publication in the last three years?

 Are you a former fellow/mentor for the applicant?

 Are you and any key personnel on the application (> 5% effort) currently at the same

institution, collaborating, and/or in a fellow/mentor relationship?

 Do you have any other conflicts reviewing this application?

Each committee reviewer must certify that to the best of his or her knowledge he/she has

disclosed all conflicts of interest that he or she may have with the applications; he or she fully

understands the confidential nature of the review process and agrees to the following:

 To destroy or return all materials related to it;

 Not to disclose or discuss the materials associated with the review, the evaluation, or the

review meeting with any other individual.

 Not to disclose procurement information.

 To refer all inquiries concerning the review to the chairperson or Foundation staff.

 To review the Foundation’s “Guidelines for Maintaining Research and Peer Review

Integrity”

Taken together, these steps attempt to avoid conflicts of interest among members of the

committee.

NOTIFICATION

An award or declination communication will be sent to the applicant informing about the

application outcome. A detailed critique summarizing the committee's deliberations will also be

provided to the applicant. Applications that are not funded may be revised and resubmitted within

a 3 year time period from the date of the initial submission. However, only two resubmissions are

allowed. Resubmitted applications will be reviewed in the same detail and compete on an equal

basis with all other new applications.

REPORTING REQUIREMENTS

Progress Reports – Interim and Final

Awardees are required to submit one progress report per project year and one final scientific

report summarizing the progress made toward achieving the proposed goals and outcomes.

Second and third year funding is contingent upon the favorable evaluation of the first and second

years’ progress reports. The final scientific report is due 90 days after the end of the project.

Payments will not be processed while progress reports are delinquent.

Progress reports are due 10 months after the start date of the current year of the award. Reports

should follow the template provided in proposalCENTRAL and available for download on the

Foundation’s website. If the report lists any publication, please include an electronic copy at the

end of the report. If an electronic copy is not available, please briefly explain why.

Financial Reports

Annual financial reports are due 3 months after the end of the annual budget period. To allow for

year-to-year comparison, the report should be submitted on the template provided in

proposalCENTRAL and signed by a Financial Officer at the awardee institution. Failure in

observing these requirements may delay payment.

Final payments will not be made for awards with delinquent deliverables.

ADDITIONAL AWARD POLICIES AND REQUIREMENTS

Policy on no-cost extension

In the event the research is delayed, an extension is required and a no-cost extension request

form and documentation must be e-mailed to grant@crohnscolitisfoundation.org no later than 60

days before the end of the project period. This request must be made on institutional letterhead

and signed by both the PI and the Institutional Official.

Multiple no-cost extensions may be considered based on the research involved.

Please ensure that annual progress and financial reports have been uploaded in

proposalCENTRAL before submitting a no-cost extension request, as requests will not be

considered for awards with outstanding required reports.

The no-cost extension request form and instructions are available on the Foundation’s website.

Policy on publications and award acknowledgment

Publications resulting from research activities supported by the Foundation should contain the

following acknowledgement:

Supported by the Crohn’s & Colitis Foundation, award number xxxxxx, project title xxxxx.

The Foundation’s support should also be acknowledged by the awardee and by the awardee

institution in all public communication of work resulting from this grant, including scientific

abstracts (where permitted), posters at scientific meetings, press releases or other media

communications, and Internet-based communications.

The Foundation shall receive timely and prior notice of any publications based upon the funded

research and a copy of the publication should be uploaded onto the award record in

proposalCENTRAL.

Policy on patents and intellectual property

It is understood that submission of a proposal for funding consideration indicates that both PI and

Institution are informed of and agree with the Foundation’s Patent and Intellectual Property Policy,

available for download on the Foundation’s website.

Policy on award transfer

Recipients may transfer their grant from one institution to another. Projects that have been funded

for six months or longer will be reviewed by an administrative committee after full details of the

new environment and budget have been provided.

The change of institution request form and instructions are available on the Foundation’s website

or contact grant@crohnscolitisfoundation.org.

Policy on carryforward

Carryforward into the next budget year is allowed up to 30% of the annual budget.

Carryforward requests for amounts above this threshold will be considered on a case-by-case

basis and must be requested in writing to the Foundation staff no later than 60 days before the

end of the budget period. This request must be made on institutional letterhead and signed by

both the PI and the Institutional Official.

Policy on return of funds

Unspent balances at the end of the project of up to $100 (one hundred dollars) can remain at the

awardee institution and be allocated to support the PI’s research efforts.

Unspent balances at the end of the project of more than $100 (one hundred dollars) must be

returned in full to the Foundation.

Withdrawal of Application

Applicants are asked to notify the Foundation in writing should they decide to withdraw their

applications for any reason.

Change of Address

Applicants are responsible for notifying the Foundation in writing of any changes of address, email

or phone number, following the submission of an application.